Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Nicholas A. Magnus is active.

Publication


Featured researches published by Nicholas A. Magnus.


Tetrahedron Letters | 2000

A new asymmetric 1,4-addition method: application to the synthesis of the HIV non-nucleoside reverse transcriptase inhibitor DPC 961

Nicholas A. Magnus; Pat N. Confalone; Louis Storace

Abstract The asymmetric synthesis of the HIV non-nucleoside reverse transcriptase inhibitor (NNRTI) DPC 961 is achieved in three steps with an overall yield of >55%. The asymmetry is induced by the chiral auxiliary (R)-(+)-α-methylbenzylamine, utilizing a new asymmetric 1,4-addition protocol.


Organic Letters | 2010

Pictet-Spengler based synthesis of a bisarylmaleimide glycogen synthase kinase-3 inhibitor.

Nicholas A. Magnus; Christopher P. Ley; Patrick M. Pollock; James P. Wepsiec

A practical synthesis of the glycogen synthase kinase-3 (GSK3) inhibitor bisarylmaleimide 1 has been accomplished employing Pictet-Spengler methodology to access the indole 7-position in preparing the benzodiazepine tricyclic fragment. A seven-step linear sequence that starts with commercially available 5-fluoroindole 7 affords the bisarylmaleimide 1 in 33% overall yield.


Journal of Organic Chemistry | 2013

Additives promote Noyori-type reductions of a β-keto-γ-lactam: asymmetric syntheses of serotonin norepinephrine reuptake inhibitors.

Nicholas A. Magnus; Bret A. Astleford; Dana L. T. Laird; Todd D. Maloney; Adam D. McFarland; John R. Rizzo; J. Craig Ruble; Gregory A. Stephenson; James P. Wepsiec

Serotonin norepinephrine reuptake inhibitor (SNRI) pyrrolidinyl ether 2 was synthesized by employing a dynamic kinetic resolution (DKR) with enantio- and diastereoselective hydogenation on β-keto-γ-lactam 8 to afford β-hydroxy-γ-lactam 9 with 96% ee and 94% de. Reduction of 9 and purification via the dibenzoyl-(L)-tartaric acid diastereomeric salt 16 enriched the ee and de to 100%. While screening hydrogenation reaction systems with ruthenium-BINAP catalysts to prepare 9, it was found that adding catalytic HCl and LiCl enabled higher yields. In addition, the rate and equilibrium of the DKR-hydrogenation of 8 to give 9 was studied by online NMR and chiral HPLC, which indicated that one of the enantiomers of 8 was reducing faster to 9 than the equilibration of the stereocenter of 8.


Journal of Organic Chemistry | 2017

Cyclization of Methyl-Coumalate-Derived Methyl 1-Benzamido-6-oxo-1,6-dihydropyridine-3-carboxylates: Assembly of the [1,2,4]Triazolo[1,5-a]pyridine Ring System

Harold Moloney; Nicholas A. Magnus; Jonas Y. Buser; Matthew C Embry

An efficient three-step synthesis of a series of fused bicyclic s-[1,2,4]triazolo[1,5-a]pyridines 1 was accomplished utilizing novel intermediates derived from inexpensive, commercially available hydrazides A and methyl coumalate B. A significant feature of this approach was the formation of a dihydrazide intermediate 2, bypassing the need for oxidative N-N bond formation in the 1,2,4-triazole synthesis. Further purification of the dihydrazides 2, beyond simple isolation, proved to be unnecessary owing to the impurity rejection afforded by the crystalline oxadiazolium salts 3. Additionally, the prepared oxadiazolium perchlorate salts showed excellent moisture stability, an unusual feature in compounds of this type.


Organic Letters | 2000

An Efficient Chiral Moderator Prepared from Inexpensive (+)-3-Carene: Synthesis of the HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor DPC 963

Goss S. Kauffman; Gregory D. Harris; Roberta L. Dorow; Benjamin R. P. Stone; Rodney L. Parsons; Jaan A. Pesti; Nicholas A. Magnus; Joseph M. Fortunak; Pat N. Confalone; William A. Nugent


Organic Process Research & Development | 2007

Optimized catalytic enantioselective aryl transfer process gives access to mGlu2 receptor potentiators

Nicholas A. Magnus; Peter B. Anzeveno; D. Scott Coffey; David A. Hay; Michael E. Laurila; Jeffrey M. Schkeryantz; Bruce W. Shaw; Michael A. Staszak


Organic Process Research & Development | 2007

The Synthesis of a 5HT2C Receptor Agonist

Lindsay A. Hobson; William A. Nugent; Stephen R. Anderson; Subodh S. Deshmukh; James J. Haley; Pingli Liu; Nicholas A. Magnus; Patrick J. Sheeran; James P. Sherbine; Benjamin R. P. Stone; Jiang Zhu


Organic Process Research & Development | 2009

Green N-Methylation of Electron Deficient Pyrroles with Dimethylcarbonate

Michael L. Laurila; Nicholas A. Magnus; Michael A. Staszak


Organic Process Research & Development | 2012

Development of an Enantioselective Hydrogenation Based Synthesis of a Glucokinase Activator

Nicholas A. Magnus; Timothy M. Braden; Jonas Y. Buser; Amy C. DeBaillie; Perry Clark Heath; Christopher P. Ley; Jacob R. Remacle; David L. Varie; Thomas Michael Wilson


Organic Process Research & Development | 2012

An Asymmetric Synthesis of a Chiral Sulfone Acid with Concomitant Hydrolysis and Oxidation to Enable the Preparation of a Glucokinase Activator

Amy C. DeBaillie; Nicholas A. Magnus; Michael E. Laurila; James P. Wepsiec; J. Craig Ruble; Jeffrey J. Petkus; Radhe K. Vaid; Jeffry K. Niemeier; Joseph F. Mick; Thomas Z. Gunter

Collaboration


Dive into the Nicholas A. Magnus's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge